Drug Profile
Research programme: daptomycin/tedizolid
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Trius Therapeutics
- Developer Cubist Pharmaceuticals
- Class Cyclic peptides; Lipopeptides; Oxazolidinones
- Mechanism of Action Cell wall inhibitors; Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
- 11 Sep 2013 Trius Therapeutics has been acquired and merged into Cubist Pharmaceuticals